Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

Autor: Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund

Publikováno v: Acta Oncologica, Vol 63, Iss 1 (2024)

Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of

Externí odkaz: https://doaj.org/article/340dd2f28c5441ddaf0adaf8e0022afa

Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy - The randomized NORDIC9-study

Autor: Gabor Liposits, Jesper Ryg, Halla Skuladottir, Stine B. Winther, Sören Möller, Eva Hofsli, Carl-Henrik Shah, Laurids Østergaard Poulsen, Åke Berglund, Camilla Qvortrup, Pia Osterlund, Bengt Glimelius, Halfdan Sorbye, Per Pfeiffer

Publikováno v: Liposits, G, Ryg, J, Skuladottir, H, Winther, S B, Möller, S, Hofsli, E, Shah, C-H, Poulsen, L Ø, Berglund, Å, Qvortrup, C, Osterlund, P, Glimelius, B, Sorbye, H & Pfeiffer, P 2023, ' Prognostic value of baseline functional status measures and geriatric screening in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy-The randomized NORDIC9-study ', Journal of geriatric oncology, vol. 14, no. 1, 101408 . https://doi.org/10.1016/j.jgo.2022.11.007
Journal of Geriatric Oncology

Introduction: Appropriate patient selection based on functional status is crucial when considering older adults for palliative chemotherapy. This pre-planned analysis of the randomized NORDIC9-study explored the prognostic value of four functional st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::059d2ec63a3f9fb92e997e0bd98c7813
https://vbn.aau.dk/da/publications/6bf47703-91e6-4eaf-978d-3f4f88c09204

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9):a randomised, open-label phase 2 trial

Autor: Halfdan Sorbye, Jesper Ryg, Bengt Glimelius, Åke Berglund, Laurids Østergaard Poulsen, Carl Henrik Shah, Gabor Liposits, Eva Hofsli, Stine Braendegaard Winther, Camilla Qvortrup, Per Pfeiffer, Pia Österlund, Halla Skuladottir

Publikováno v: Winther, S B, Liposits, G, Skuladottir, H, Hofsli, E, Shah, C H, Poulsen, L Ø, Ryg, J, Osterlund, P, Berglund, Å, Qvortrup, C, Glimelius, B, Sorbye, H & Pfeiffer, P 2019, ' Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 4, no. 5, pp. 376-388 . https://doi.org/10.1016/S2468-1253(19)30041-X
Winther, S B, Liposits, G, Skuladottir, H, Hofsli, E, Shah, C-H, Poulsen, L Ø, Ryg, J, Osterlund, P, Berglund, Å, Qvortrup, C, Glimelius, B, Sorbye, H & Pfeiffer, P 2019, ' Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9) : a randomised, open-label phase 2 trial ', The Lancet Gastroenterology & Hepatology, vol. 4, no. 5, pp. 376-388 . https://doi.org/10.1016/S2468-1253(19)30041-X

Background: Older or vulnerable patients with metastatic colorectal cancer are seldom included in randomised trials. The multicentre NORDIC9 trial evaluated reduced-dose combination chemotherapy compared with full-dose monotherapy in older, vulnerabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab0f3e0a6eb85de94e3ecfd4fc1adfa
https://portal.findresearcher.sdu.dk/da/publications/4a0bf36a-aa09-4a15-827f-933c4d2d5f1a

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

Autor: Niels Viggo Jensen, Helle Pappot, Anders Ullén, Carl Henrik Shah, Karin Holmsten, L.H. Dohn, Fredrik Jäderling

Publikováno v: Oncology Letters
Holmsten, K, Dohn, L, Jensen, N V, Shah, C-H, Jäderling, F, Pappot, H & Ullén, A 2016, ' Vinflunine treatment in patients with metastatic urothelial cancer : A Nordic retrospective multicenter analysis ', Oncology Letters, vol. 12, no. 2, pp. 1293-1300 . https://doi.org/10.3892/ol.2016.4775

In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d3bd4790fe5a47e75655f246c4a474
http://europepmc.org/articles/PMC4950730

Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors

Autor: Gabor Liposits, Raymond S. McDermott, Raija Kallio, Halfdan Sorbye, Bengt Glimelius, Johannes J.M. Kwakman, Annika Ålgars, Erik van Werkhoven, T. Salminen, Rebecka Röckert, Petra Flygare, Cornelis J. A. Punt, Helga Hagman, Eetu Heervä, Per Pfeiffer, P. Halonen, L. M. Soveri, Sampsa Kinos, Carl-Henrik Shah, Pia Österlund

Publikováno v: Österlund, P, Kinos, S, Halonen, P, Soveri, L-M, Kwakman, J J, Salminen, T, McDermott, R S, Pfeiffer, P, Heervä, E, Istvan Liposits, G, Röckert, R, Ålgars, A, Kallio, R S, Sorbye, H, Flygare, P, Hagman, H, Shah, C-H, Werkhoven, E D V, Glimelius, B, Punt, C J A & Cardioswitch Group 2020, ' Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. ', Journal of Clinical Oncology, vol. 38, no. 15 Suppl., pp. 7037 . https://doi.org/10.1200/jco.2020.38.15_suppl.7037

7037 Background: Fluoropyrimidines (FP) are the cornerstone of chemotherapy in many solid tumors and linked to cardiotoxicity (CarTx) in about 5% (Polk, Cancer Treat Rev 2013), often leading to FP discontinuation. CarTx may be less common with S-1 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2687921bc5fce0128f6fa74dcbc3bc
https://doi.org/10.1200/jco.2020.38.15_suppl.7037